Lynn Schuchter

Lynn Schuchter

UNVERIFIED PROFILE

Are you Lynn Schuchter?   Register this Author

Register author
Lynn Schuchter

Lynn Schuchter

Publications by authors named "Lynn Schuchter"

Are you Lynn Schuchter?   Register this Author

100Publications

12901Reads

49Profile Views

Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.

Ann Surg Oncol 2019 Jul 3. Epub 2019 Jul 3.

Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07599-yDOI Listing
July 2019

ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH Melanoma-Initiating Cells.

Cell Chem Biol 2018 12 4;25(12):1456-1469.e6. Epub 2018 Oct 4.

MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24519456183030
Publisher Site
http://dx.doi.org/10.1016/j.chembiol.2018.09.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309505PMC
December 2018

Best Practices for Reducing Unplanned Acute Care for Patients With Cancer.

J Oncol Pract 2018 05 17;14(5):306-313. Epub 2018 Apr 17.

University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.17.00081
Publisher Site
http://dx.doi.org/10.1200/JOP.17.00081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366244PMC
May 2018

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018

Acute visual loss after ipilimumab treatment for metastatic melanoma.

J Immunother Cancer 2016 18;4:66. Epub 2016 Oct 18.

Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA USA ; Present address: Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, C366 MIB 1500 E. Medical Center Drive, SPC5848, Ann Arbor, MI 48109 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0170-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067900PMC
February 2018

Adjuvant Melanoma Therapy - Head-Spinning Progress.

Authors:
Lynn M Schuchter

N Engl J Med 2017 11;377(19):1888-1890

From the University of Pennsylvania Abramson Cancer Center, Philadelphia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1711199DOI Listing
November 2017

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

J Clin Oncol 2017 04 1;35(12):1341-1367. Epub 2017 Feb 1.

Harold J. Burstein and Steven G. DuBois, Dana-Farber Cancer Institute; Rebecca A. Miksad and Nadine Tung, Beth Israel Deaconess Medical Center; Lori J. Wirth and Don S. Dizon, Massachusetts General Hospital, Boston, MA; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria; Jeanny B. Aragon-Ching, Inova Schar Cancer Institute, Fairfax, VA; E. Gabriela Chiorean, University of Washington, Seattle, WA; Warren Allen Chow, City of Hope, Duarte, CA; John Frederick De Groot and John Heymach, University of Texas MD Anderson Cancer Center, Houston, TX; Steven Michael Devine, Ohio State University, Columbus; Nathan A. Pennell, Cleveland Clinic, Cleveland, OH; Wafik S. El-Deiry, Fox Chase Cancer Center; Joshua Adam Jones, University of Pennsylvania Health Systems; Lynn Mara Schuchter, University of Pennsylvania, Philadelphia, PA; Andrew S. Epstein, Memorial Sloan Kettering Cancer Center, New York, NY; Deborah K. Mayer, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Karen Marie Winkfield, Wake Forest Baptist Medical Center, Winston-Salem, NC; Michael S. Sabel, University of Michigan, Ann Arbor, MI; and Nancy N. Baxter, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5292DOI Listing
April 2017

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.

J Clin Oncol 2017 01 28;35(2):139-140. Epub 2016 Nov 28.

Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Laura A. Levit, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, The Children's Hospital of Philadelphia, Philadelphia, PA; Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Adam P. Dicker, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA; Mithat Gönen, Memorial Sloan Kettering Cancer Center, New York, NY; Stephen M. Keefe, University of Pennsylvania, Philadelphia, PA; Michael A. Postow, Memorial Sloan Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC; and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559890PMC
January 2017

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

Cell 2016 Dec;167(6):1540-1554.e12

Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2016.11.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385895PMC
December 2016

Histopathologic and mutational analysis of a case of blue nevus-like melanoma.

J Cutan Pathol 2016 Sep 8;43(9):776-80. Epub 2016 Jun 8.

Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.12731DOI Listing
September 2016

Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.

J Cutan Pathol 2016 Sep 1;43(9):787-91. Epub 2016 Jun 1.

Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.12735DOI Listing
September 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.

Clin Cancer Res 2016 Jan 25;22(2):374-82. Epub 2015 Aug 25.

Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821426PMC
January 2016

Chemotherapy for Melanoma.

Cancer Treat Res 2016 ;167:209-29

Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center of the University of Pennsylvania, 3400 Civic Center Blvd, 1218 Penn Tower, Philadelphia, PA, 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-22539-5_8DOI Listing
January 2016

Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.

Oncologist 2016 Jan 27;21(1):84-94. Epub 2015 Nov 27.

Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709205PMC
January 2016

Improving the Safety of Oral Chemotherapy at an Academic Medical Center.

J Oncol Pract 2016 Jan 5;12(1):e71-6. Epub 2016 Jan 5.

Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2015.007260DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960462PMC
January 2016

Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.

Oncologist 2015 Aug 17;20(8):952-9. Epub 2015 Jun 17.

Developmental Therapeutics Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Cancer Therapeutics Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524755PMC
August 2015

Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status.

JAMA Oncol 2015 Jul;1(4):427-8

Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.1237DOI Listing
July 2015

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.

Cancer J 2014 Jan-Feb;20(1):18-24

From the *Karmanos Cancer Center, Wayne State University, Detroit, MI; †The Angeles Clinic and Research Institute, Los Angeles, CA; ‡Washington University, St Louis, MO; §University of Pennsylvania, Philadelphia, PA; ∥Oncology Specialists S.C., Park Ridge, IL; ¶University of Colorado Cancer Center, Aurora, CO; #Baylor Sammons Cancer Center, Texas Oncology, PA, Dallas, TX; **NYU Medical Center, New York, NY; ††South Carolina Oncology Associates, Columbia, SC; ‡‡Providence Portland Medical Center, Portland, OR; §§Winship Cancer Institute, Emory University, Atlanta, GA; ∥∥Memorial Sloan Kettering Cancer Center, New York, NY; ¶¶Seattle Cancer Care Alliance, Seattle, WA; ##UCLA School of Medicine, Los Angeles, CA; ***Beth Israel Deaconess Medical Center and †††Massachusetts General Hospital, Boston, MA; ‡‡‡University of Arizona Cancer Center, Tucson, AZ; §§§Dana Farber Cancer Institute, Boston, MA; ∥∥∥Genentech, San Francisco, CA; ¶¶¶The SFJ Pharma Group, Pleasanton, CA; and ###Sarah Cannon Research Institute, Nashville, TN.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2014/01000/A_Single_
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705837PMC
May 2015

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Nature 2015 Apr 9;520(7547):373-7. Epub 2015 Mar 9.

1] Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [2] Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [3] Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [4] Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401634PMC
April 2015

IL-8 and cathepsin B as melanoma serum biomarkers.

Int J Mol Sci 2011 25;12(3):1505-18. Epub 2011 Feb 25.

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; E-Mails: (T.F.); (S.K.); (S.L.); (X.X.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms12031505DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111615PMC
January 2015

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

J Clin Oncol 2015 Jan 15;33(3):278-84. Epub 2014 Dec 15.

Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa, FL; Laura A. Levit and Suanna Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, Children's Hospital of Philadelphia; Adam P. Dicker, Jefferson Medical College, Thomas Jefferson University; Stephen M. Keefe and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA; Howard A. Burris IIII, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD; Mithat Gönen and Michael A. Postow, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; and Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/3/278.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.2635
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.2635DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516884PMC
January 2015

Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.

J Mol Biomark Diagn 2014 Nov;4(3):151

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4172/2155-9929.1000151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114390PMC
November 2014

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.

Cancer Immunol Res 2014 Nov 24;2(11):1051-8. Epub 2014 Sep 24.

Abramson Cancer Center, University of Pennsylvania, Philadelphia. Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221425PMC
November 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Ipilimumab-associated Sweet syndrome in a melanoma patient.

J Am Acad Dermatol 2014 Nov 15;71(5):e211-3. Epub 2014 Oct 15.

Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2014.06.042DOI Listing
November 2014

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.

Clin Cancer Res 2014 Jun 8;20(12):3328-37. Epub 2014 Apr 8.

Authors' Affiliations: Hematology/Oncology, Department of Medicine, University of Pennsylvania; Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania, Philadelphia; University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; Dana Farber Cancer Institute; Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Yale University School of Medicine; and Section of Medical Oncology, Yale Cancer Center, New Haven, ConnecticutAuthors' Affiliations: Hematology/Oncology, Department of Medicine, University of Pennsylvania; Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania, Philadelphia; University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; Dana Farber Cancer Institute; Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Yale University School of Medicine; and Section of Medical Oncology, Yale Cancer Center, New Haven, Connecticut

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058354PMC
June 2014

What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing.

Cancer Genet 2014 Jun 18;207(6):272-5. Epub 2014 Jun 18.

Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2014.06.022DOI Listing
June 2014

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

Cancer Discov 2013 Dec 8;3(12):1378-93. Epub 2013 Oct 8.

1Tumor Metastasis and Microenvironment Program and 2Molecular and Cellular Oncogenesis Program, The Wistar Institute; 3Abramson Cancer Center, University of Pennsylvania, Philadelphia; 4Lehigh Valley Health Network, Allentown, Pennsylvania; 5The National Institute on Aging, NIH, Baltimore, Maryland; and 6Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918498PMC
December 2013

Local immune response predicts survival in patients with thick (t4) melanomas.

Ann Surg Oncol 2013 Oct 10;20(11):3610-7. Epub 2013 Jul 10.

Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-013-3086-3DOI Listing
October 2013

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.

J Clin Invest 2013 May 1;123(5):2155-68. Epub 2013 Apr 1.

Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI65780DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635724PMC
May 2013

Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors.

Cancer Epidemiol Biomarkers Prev 2013 Apr 7;22(4):607-14. Epub 2013 Feb 7.

Perelman School of Medicine and School of Nursing, University of Pennsylvania, 801 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-12-1174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617083PMC
April 2013

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

J Am Acad Dermatol 2012 Dec 18;67(6):1265-72. Epub 2012 May 18.

Department of Dermatology, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2012.04.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838029PMC
December 2012

Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma.

Clin Cancer Res 2012 Jan 17;18(1):229-37. Epub 2011 Nov 17.

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-0490DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262994PMC
January 2012

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.

Cancer Chemother Pharmacol 2011 Nov 25;68(5):1111-8. Epub 2011 Feb 25.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1585-0DOI Listing
November 2011

Does MC1R genotype convey information about melanoma risk beyond risk phenotypes?

Cancer 2010 May;116(10):2416-28

Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864335PMC
May 2010

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.

Clin Cancer Res 2009 Dec;15(24):7711-7718

Authors' Affiliations: Abramson Cancer Center at the University of Pennsylvania and Department of Medicine, Division of Medical Genetics, University of Pennsylvania, Philadelphia, Pennsylvania; and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795076PMC
December 2009

Drug targeting of oncogenic pathways in melanoma.

Hematol Oncol Clin North Am 2009 Jun;23(3):599-618, x

Department of Medicine, Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S088985880900040
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2009.03.004DOI Listing
June 2009

Effectively targeting BRAF in melanoma: a formidable challenge.

Pigment Cell Melanoma Res 2008 Aug;21(4):410-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1755-148X.2008.00485.xDOI Listing
August 2008

Meeting report: fourth international congress of the Society for Melanoma Research.

Pigment Cell Melanoma Res 2008 Feb;21(1):15-26

Department of Pediatric Hematology/Oncology and Melanoma Program, Dana-Farber Cancer Institute and Children's Hospital of Boston, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1755-148X.2007.00437.xDOI Listing
February 2008